Cover Image
市場調查報告書

Dendreon Corporation的產品平台分析

Dendreon Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 224609
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Dendreon Corporation的產品平台分析 Dendreon Corporation - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 32 Pages
簡介

Dendreon Corporation是開發階段的生物科技企業,正在開發癌症及其他危及生命重大疾病的治療用醫藥品。

本報告提供Dendreon Corporation上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Dendreon Corporation的基本資料

Dendreon Corporation概要

  • 主要資訊
  • 企業資料

Dendreon Corporation:R&D概要

  • 主要的治療範圍

Dendreon Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Dendreon Corporation:開發中產品概況

  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式

Dendreon Corporation:藥物簡介

  • lapuleucel-t
  • D-3263
  • 以碳酸脫水酵素IX為標的的藥物
  • 以癌胚胎抗原為標的的藥物

Dendreon Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Dendreon Corporation:最近的開發平台趨勢

Dendreon Corporation:暫停中的計劃

Dendreon Corporation:中止開發的開發中產品

  • UK-279276

Dendreon Corporation:企業發表

Dendreon Corporation:總公司和子公司的所在地

Dendreon Corporation:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04886CDB

Global Markets Direct's, 'Dendreon Corporation - Product Pipeline Review - 2014', provides an overview of the Dendreon Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dendreon Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dendreon Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dendreon Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dendreon Corporation's pipeline products

Reasons to buy

  • Evaluate Dendreon Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dendreon Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dendreon Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dendreon Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dendreon Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dendreon Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dendreon Corporation Snapshot
    • Dendreon Corporation Overview
    • Key Information
    • Key Facts
  • Dendreon Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Dendreon Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Dendreon Corporation - Pipeline Products Glance
    • Dendreon Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Dendreon Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Dendreon Corporation - Drug Profiles
    • lapuleucel-t
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • D-3263
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting Carbonic Anhydrase IX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting Carcinoembryonic Antigen
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dendreon Corporation - Pipeline Analysis
    • Dendreon Corporation - Pipeline Products by Target
    • Dendreon Corporation - Pipeline Products by Route of Administration
    • Dendreon Corporation - Pipeline Products by Molecule Type
    • Dendreon Corporation - Pipeline Products by Mechanism of Action
  • Dendreon Corporation - Recent Pipeline Updates
  • Dendreon Corporation - Dormant Projects
  • Dendreon Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • UK-279276
  • Dendreon Corporation - Company Statement
  • Dendreon Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Dendreon Corporation - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dendreon Corporation, Key Information
  • Dendreon Corporation, Key Facts
  • Dendreon Corporation - Pipeline by Indication, 2014
  • Dendreon Corporation - Pipeline by Stage of Development, 2014
  • Dendreon Corporation - Monotherapy Products in Pipeline, 2014
  • Dendreon Corporation - Phase II, 2014
  • Dendreon Corporation - Phase I, 2014
  • Dendreon Corporation - Preclinical, 2014
  • Dendreon Corporation - Pipeline by Target, 2014
  • Dendreon Corporation - Pipeline by Route of Administration, 2014
  • Dendreon Corporation - Pipeline by Molecule Type, 2014
  • Dendreon Corporation - Pipeline Products by Mechanism of Action, 2014
  • Dendreon Corporation - Recent Pipeline Updates, 2014
  • Dendreon Corporation - Dormant Developmental Projects,2014
  • Dendreon Corporation - Discontinued Pipeline Products, 2014
  • Dendreon Corporation, Subsidiaries
  • Dendreon Corporation, Key Manufacturing Facilities

List of Figures

  • Dendreon Corporation - Pipeline by Top 10 Indication, 2014
  • Dendreon Corporation - Pipeline by Stage of Development, 2014
  • Dendreon Corporation - Monotherapy Products in Pipeline, 2014
  • Dendreon Corporation - Pipeline by Top 10 Target, 2014
  • Dendreon Corporation - Pipeline by Top 10 Route of Administration, 2014
  • Dendreon Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Dendreon Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top